ZOAR Stock Forecast: Zoar Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 18 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Zoar Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (71): Sales and profits are climbing, and climbing faster than before.
Volatility (9): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ZOAR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ZOAR, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
ZOAR appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ZOAR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 8.4×
- Price / sales
- —
- Price / book
- 5.2×
- EV / EBITDA
- —
Cheaper than 78% of US stocks
Cheaper than 17% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- 71.2%
- Return on assets
- −17.3%
- Dividend yield
- —
Higher than 95% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Zoar Ltd. has a market value of $653.4M.
Revenue in the twelve months to 30 June 2026: $35K. The latest quarter shrank 57.1% year on year.
Net income over the same four quarters: $776K, a 2217.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$508K.
Trailing P/E: 8.4×.
Data provided by Twelve Data
ZOAR and its peers
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| ZOARZoar Ltd. | $653.4M | 18 |
| OGNOrganon & Co. | $3.6B | 92 |
| JANXJanux Therapeutics, Inc.* | $606.3M | 73 |
| OLMAOlema Oncology, Inc.* | $611.8M | 25 |
| KURAKura Oncology, Inc.* | $613.4M | 53 |
| ABUSArbutus Biopharma Corp.* | $616.2M | 82 |
| IAMIambic Therapeutics, Inc.* | $621.4M | 1 |
* Nearest Healthcare names by size — few drug manufacturers - general companies of this scale trade in the US universe.
Take a look at ZOAR’s peer groups, ranked by the model: consumer cyclical stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Zoar Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ZOAR
How does Ticker Nerd's model rank ZOAR?
As at 21 Nov 2026, Zoar Ltd. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (71 of 100).
What is the ZOAR stock forecast for 2030?
No analyst covering Zoar Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZOAR are extrapolating price history, which says nothing about the business.
What does Zoar Ltd. do?
Zoar Limited is a pharmaceutical company focused on developing and manufacturing complex active pharmaceutical ingredients and intermediates used in drug production. Through its operating businesses, the company also provides contract development and manufacturing services to pharmaceutical and biotechnology companies, supporting activities ranging from process development and formulation work to commercial-scale production.
About Zoar Ltd.
Zoar Limited is a pharmaceutical company focused on developing and manufacturing complex active pharmaceutical ingredients and intermediates used in drug production. Through its operating businesses, the company also provides contract development and manufacturing services to pharmaceutical and biotechnology companies, supporting activities ranging from process development and formulation work to commercial-scale production. Its capabilities serve partners that require specialized chemistry, manufacturing expertise, quality-controlled production, and dependable supply of pharmaceutical inputs. Zoar Limited operates across the global pharmaceutical services market, where API manufacturers and contract development and manufacturing organizations play an important role in helping drug developers advance products from laboratory research toward broader production. The company’s business also encompasses pharmaceutical research and development activities associated with specialty therapeutic areas, including neurological, oncological, and immune-related conditions. Headquartered in Grand Cayman, the Cayman Islands, Zoar Limited combines pharmaceutical manufacturing, technical development, and outsourced production services within an industry that supports both established drug companies and emerging biotechnology businesses.
CEO Mr. Frank D. Heuszel Esq., J.D. · Hong Kong · https://zoarlimited.com